Kairax Dermal Fillers
Cross-linked Hyaluronic Acid Matrix with 24mg/ml Concentration ±0.3% Lidocaine
Advanced Vycrossâ„¢ Technology
Utilizing patented 1,4-Butanediol Diglycidyl Ether cross-linking (US Patent 9,724,342), Kairax fillers demonstrate 87% HA persistence at 12 months with G‧ values ranging from 150-600Pa. The monophasic formula maintains 98% structural integrity during injection through 30G needles. Third-party studies show 0.08% particulate matter content meeting ISO 13485 medical device standards.
Product Matrix Specifications
Kairax Fine
G‧ 150-200Pa | For superficial wrinkles (depth ≤1mm)
Applications:
– Periorbital lines
– Crow’s feet
– Lip contour
Kairax Deep
G‧ 300-400Pa | For deep folds (depth 2-4mm)
Applications:
– Glabella lines
– Nasolabial folds
– Marionette lines
Kairax Sub-Q
G‧ 500-600Pa | For volumetric restoration
Applications:
– Cheek augmentation
– Jaw contouring
– Body sculpting
Product Specifications
- HA Concentration: 24mg/ml ±5%
- Lidocaine: 0.3% w/w
- Needles: 2×30G ½”
- Sterility: Terminal EO gas sterilization
- Storage: 2-25°C horizontal position
- Shelf Life: 24 months unopened
Clinical Protocol
- Needle: 30G ½” for precision work
- Depth: Mid-dermal to subdermal
- Max Volume: 1ml/session
- Anesthesia: Not required (pre-incorporated)
- Follow-up: 2-4 week assessment
Medical Advisory
Note: Results may vary ±25% based on individual tissue response. For use exclusively by licensed aesthetic practitioners. Contraindicated in patients with active skin infections or hypersensitivity to gram-positive bacterial proteins.
Immediate medical attention required if vascular compromise suspected. Not for use in vascular danger zones without ultrasound guidance. MRI safety established for static fields ≤3T.
Reviews
There are no reviews yet.